DARPA Funds $6.8M Program to Map How Psychedelics Rewire Fear Circuits

The Program

DARPA has awarded $6.8 million through its Targeted Neuroplasticity Training (TNT) program extension to Johns Hopkins University and the Icahn School of Medicine at Mount Sinai. The goal: map exactly how psilocybin and MDMA alter the neural circuits involved in fear learning and extinction.

This isn't a clinical trial. It's basic neuroscience — using advanced calcium imaging, optogenetics, and high-density electrophysiology to understand why these compounds work, not just whether they work.

Why DARPA Cares

PTSD affects an estimated 11-20% of veterans returning from Iraq and Afghanistan deployments. Current treatments — prolonged exposure therapy, cognitive processing therapy, SSRIs — have failure rates between 30-50%. The military has a direct operational interest in better solutions.

The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in 2019 and to MDMA-assisted therapy for PTSD in 2017. Clinical data from MAPS Phase III trials showed that 67% of PTSD patients no longer met diagnostic criteria after three MDMA-assisted therapy sessions.

But the mechanism remains poorly understood. How do these compounds enable fear extinction in a single session when traditional therapy takes months? DARPA wants circuit-level answers.

What They're Looking For

The research will focus on three specific questions:

1. Critical period reopening. Psilocybin appears to reopen critical periods of neural plasticity — windows of heightened learning that normally close in early development. The Johns Hopkins team will map which circuits undergo plasticity changes and how long the window stays open.

2. Fear memory reconsolidation. When a traumatic memory is recalled under the influence of MDMA, it appears to be "reconsolidated" with reduced emotional valence. The Mount Sinai team will track amygdala-prefrontal connectivity changes during reconsolidation to understand the mechanism.

3. Default mode network disruption. Both compounds acutely reduce default mode network (DMN) coherence. The hypothesis is that DMN disruption allows rigid, trauma-associated thought patterns to become flexible and amenable to therapeutic reprocessing.

Implications

If the research identifies specific circuit mechanisms, it could lead to:

• Non-psychedelic compounds that mimic the plasticity-enhancing effects without the altered state of consciousness
• Optimized dosing protocols based on when plasticity windows open and close
• Biomarkers for predicting which patients will respond to psychedelic-assisted therapy
• Combination approaches pairing targeted neurostimulation with sub-perceptual doses

This funding signals that the U.S. military establishment has moved past the question of "do psychedelics work for PTSD?" and is now asking "how do we optimize and scale this?"

$6.8 million from the agency that created the internet, pointed at understanding how a mushroom rewires fear. The future of trauma treatment may be stranger than we expected.